drugset / Trial / NCT07318831
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II clinical trial investigating the effectiveness and safety of a four-drug combination-Chidamide, Dinutuximab Beta, Irinotecan, and Temozolomide-for children with relapsed or refractory neuroblastoma. The primary goal is to evaluate how well this regimen works to control the cancer, while the secondary goal is to closely monitor its safety and side effects in these young patients.
Timeline
- Start
- 2026-01-06
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dinutuximab | Monoclonal antibody | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Temozolomide | Small molecule | — | — |
| Subject | Tucidinostat | Small molecule | 0.5 mg/kg | Oral |